Rubicon Research
RUBICONNSE

Rubicon Research

₹1,005.6037.70 (3.90%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
968.00
Today’s high
1,020.00
52 week low
570.75
52 week high
1,020.00
Open price
984.00
Previous close
967.90
Live volume
2,91,085
Lower circuit
804.50
Upper circuit
1,206.70

Fundamentals

Market Cap
₹16,541Cr
ROE
26.49%
P/E Ratio(TTM)
80.19
EPS(TTM)
12.52
P/B Ratio
14.41
Dividend Yield
0.00%
Industry P/E
33.76
Book Value
69.66
Debt to Equity
0.88
Face Value
1

Financial performance

Quarterly
Yearly
All Financials
MAR '26
Revenue (Cr)
₹517
+7.76%
Profit (Cr)
₹76.79
+5.48%
0150300450600
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Revenue growthValue
1Y (TTM)+44%
3Y CAGR+58%
Profit growthValue
1Y (TTM)+112%
3Y CAGR+59%

About

Rubicon Research Limited is a pharmaceutical company specializing in drug delivery technologies and developing complex formulations.;
CEO/MD
Parag Suganchand Sancheti
Founded in
2000
NSE symbol
RUBICON

Shareholding Pattern

Jul '24
Sep '25
Oct '25
Dec '25
Mar '26
Promoters
59.86%
Retail And Others
18.58%
Foreign Institutions
11.54%
Mutual Funds
7.14%
Other Domestic Institutions
2.88%

Mutual Funds Invested (2)

Livesquawk
Motilal Oswal raises Rubicon Research's TP to ₹955 citing Arinna Lifescience acquisition. Acquisition aids CNS therapy entry, US pipeline leverage, and P/E rerating to 37x.
2026
29
May
Annual Result
Release date
3
Feb
Quarterly Result
Release date
2025
13
Nov
Quarterly Result
Release date
Events calendar
View upcoming events in other stocks